Briacell Therapeutics Corp

Research Briacell Therapeutics Corp (BCT) on Bullrun: market cap CAD 37.84M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBCT
• ExchangeTO
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Market capCAD 37.84M
• Financial periodQ1 2026
• Net income-CAD 7.22M
• Free cash flow-CAD 7.97M

Valuation Snapshot

latest market cap is CAD 37.84M.

About Briacell Therapeutics Corp

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.

Frequently asked questions

What is Briacell Therapeutics Corp's market cap?

Briacell Therapeutics Corp's market capitalization is CAD 37.84M.

What does Briacell Therapeutics Corp do?

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.